Outcomes of platinum-sensitive Small Cell Lung Cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: a multi-institutional retrospective analysis.

G Genestreti¹, G Metro², H Kenmotsu³, F Carloni¹, M A Burgio⁴, C Casanova⁵, M Tiseo⁶, E Scarpi⁴, T Korkmaz⁷, <u>R Califano⁸</u>

¹Department of Medical Oncology, "Cervesi" Hospital, Cattolica, Italy; ²Department of Medical Oncology, University Hospital, Perugia, Italy; ³ Division of Thoracic Oncology, Shizouka Cancer Center Shizouka, Japan; ⁴IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; ⁵Department of Medical Oncology, "Santa Maria delle Croci" Hospital, Ravenna, Italy, ⁶Department of Medical Oncology, "Maggiore" Hospital, University of Parma, Italy; ⁷Dr. Luffi Kirdar Research and Training Hospital, Instanbul, Turkey; ⁸Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK



Disclosure

No relevant conflict of interest to declare





Background

Aggressive disease, excellent response to first-line but short-lived

2nd-line chemotherapy may produce tumour regression but the evidence for a clinical benefit is limited

Platinum-based rechallenge is commonly used for platinum-sensitive (TTP≥ 90d) disease



von Pawel et al, JCO 1999; O' Brien et al, JCO 2006; Giaccone, JCO 1988; Owonikoko et al JTO 2012; Califano et al, Drugs 2012.

Methods

Retrospective series, 7 International Institutions

112 platinum-sensitive pts treated with platinumetoposide rechallenge (Jan 2007 – Dec 2011)

Endpoints:

0

Response rate

Progression-free survival

Overall survival from rechallenge

Overall survival from diagnosis

Patients Characteristics

	No	(%)
Patients	112	100
Gender	•	
Male	73	65
Female	39	35
Median age (range) 64 (40-83)	•	
Stage at diagnosis		
Limited disease	49	44
Extensive disease	63	56
Performance status	•	
0-1	97	87
2	15	13 т

 \mathbf{O}

The Christie Research Division

First-line and Rechallenge

	No	(%)	
First-line regimen			
Cisplatin/Etoposide	61	46	
Carboplatin/Etoposide	51	54	
No of cycles (range) 5 (1-6)			
Rechallenge regimen			
Cisplatin/Etoposide	16	14	
Carboplatin/Etoposide	96	86	
No of cycles (range) 3.6 (1-7)			



Further Line of Treatment

	No	(%)
Further chemotherapy		
Yes	40	36
No	72	64
Regimen	L	
Cyclophosphamide/Adryamycin/Vincristine (VAC)	10	25
Toptecan	10	25
Other	8	20
Carboplatin/Etoposide	6	15
Cyclophosphamide/Epirubicin/Vincristine (VEC)	3	7.5
Cisplatin/Etoposide	1	2.5
Carboplatin/Irinotecan	1	2.5
Gemcitabine/Paclitaxel	1	2.5

 \mathbf{O}


The Christie Research Division

Response Rate

	No	(%)	
Response to first-line chemotherapy	ł		
Complete response	16	14	
Partial response	94	84	
Stable disease	2	2	
Progressive disease	0	0	
Response to rechallenge chemotherapy			
Complete response	4	3	
Partial response	47	42	
Stable disease	21	19	
Progressive disease	30	27	
Not evaluable	10	9	
•	-		




PFS From Rechallenge




9


OS From Rechallenge



OS From Diagnosis




PFS from Rechallenge Subgroup Analysis



The Christie Research Division

OS from Rechallenge Subgroup Analysis



he Christie Research Division

Third-line treatment and Impact on PFS/OS

Further-line of treatment		PFS after third-line		OS after rechallenge			
	No	Events (No)	Median PFS (months) (95% Cl)	p value	Events (No)	Median OS (months) (95% CI)	p value
Antracycline based regimen	13	13	4.9 (3.0-5.2)		11	5.4 (2.1-7.7)	
Platinum/etoposide	7	7	3.8 (1.0-5.5)		5	9.7 (0.7-15.1)	
Topotecan	10	10	2.6 (1.0-5.9)	0.901	9	5.2 (1.7-7.9)	0.454



Conclusions

Higher RR, Longer PFS and OS than reported in phase III studies with Topotecan and VAC

No difference in PFS or OS for longer TTP

Rechallenge is a reasonable 2nd-line option with potentially better outcomes

Randomised studies are needed to clarify optimal management in platinum-sensitive pts



Acknowledgements

The Christie, Manchester, UK

Shizouka Cancer Center, Shizouka, Japan

Roopa Kurup

Fiona Blackhall

Paul Lorigan

Yvonne Summers

Paul Taylor

IRCSS Meldola, Italy Alberto Bongiovanni

"Cervesi" Hospital, Cattolica, Italy

Maximilian Papi

Marmara University Hospital, Istanbul, Turkey

Selkuc Seber

Kazushige Wakuda

